Collaboration of ARPA-H POSEIDON program with NCI’s Cancer Screening Research Network
Advanced Research Projects Agency for Health (ARPA-H) shared a post on LinkedIn:
“What if a simple test could save millions of lives by catching cancer early, in the comfort of your home?
Our new POSEIDON program aims to develop first-in-class, synthetic Multi-Cancer-Early Detection (MCED) tests for the most sensitive and specific stage I detection of 30+ solid tumors using only breath and/or urine samples.”
NCI Division of Cancer Prevention reshared a post by ARPA-H, adding:
“Advanced Research Projects Agency for Health (ARPA-H) POSEIDON program announced today that it will collaborate with NCI’s Cancer Screening Research Network (CSRN) to evaluate multi-cancer early detection technology developed through the POSEIDON program. National Cancer Institute (NCI) and ARPA-H signed an agreement that allows ARPA-H to present the most promising new technology for the early detection of cancer to CSRN investigators for consideration in clinical trials.
Improving the detection of cancer at early stages is a key goal for the National Cancer Plan and NCI. The newly established CSRN was created to evaluate exactly the kind of new and emerging technologies that the POSEIDON program aims to create.
Learn more about the CSRN.”
Source: ARPA-H/LinkedIn and NCI Division of Cancer Prevention/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023